|Bid||7.00 x 400|
|Ask||7.25 x 2500|
|Day's range||7.60 - 8.55|
|52-week range||6.57 - 20.05|
|PE ratio (TTM)||N/A|
|Earnings date||7 Nov 2017 - 13 Nov 2017|
|Forward dividend & yield||N/A (N/A)|
|1y target est||18.25|
The Zacks Analyst Blog Highlights: Sangamo Therapeutics, Sarepta Therapeutics, Akebia Therapeutics, Calithera Biosciences and GlycoMimetics
With the pharma and biotech sector bouncing back in 2017, here is a look at five drug stocks including Sarepta (SRPT) that are broker favorites.
The South San Francisco, California-based company said it had a loss of 17 cents per share. The results surpassed Wall Street expectations. The average estimate of three analysts surveyed by Zacks Investment ...
Zacks.com highlights: Amtech Systems, Grupo Financiero Galicia S.A., Calithera Biosciences, RedHill Biopharma and Protagonist Therapeutics
Calithera Biosciences (CALA) could be an interesting play for investors as it is seeing solid activity on the earnings estimate revision, along with decent short-term momentum.
Zacks.com featured highlights include article Kraton, aTyr Pharma, Grupo Financiero Galicia, Grupo Supervielle and Calithera Biosciences